EUVIMEDEUVIMED entdecken
Crossref

Analisi di impatto sul budget di differenti analoghi ad azione rapida dell’insulina in Italia

Elena P. Lanati, Paola La Malfa, Arianna Iorio, Francesco S. Mennini, Francesca Fanelli, Sandro Gentile

Global & Regional Health Technology Assessment: Italian; Northern Europe and Spanish · 2018

DOI: 10.1177/2284240318759418 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Global & Regional Health Technology Assessment: Italian; Northern Europe and Spanish, 2018. Verfasst von Elena P. Lanati und 5 weiteren Autor:innen. Die Arbeit nennt 10 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Rapid-acting insulins are the current standard of care in diabetes management. Insulin aspart (IA), lispro (IL) and glulisine (IG) demonstrated similar efficacy and safety. However, their impact on the National Health Service (NHS) expenditure could be a relevant differentiating factor.

Objective

The study aims to assess the budget impact of IG increased market share in a new scenario vs. current case.

Method

A budget impact model built in MS Excel (2010) estimated the impact of IG on the Italian NHS expenditure. Input data were derived from published sources. Pharmaceutical expenditure for considered treatments was estimated on retail or hospital prices and no price modifications were assumed. A scenario analysis was conducted by varying the IG market shares.

Results

In the current scenario, IG market share 17.2%, the NHS expenditure is respectively €245-250 million at first and third year. Increasing the IG market share of 35% more of the current scenario, at first year and more of 50% at the following two years, the NHS expenditure reduces to €244.3, €245.0 and €244.8 million in the three years with cumulative, savings around € 8.8 million at third year. The scenario analysis shows that, increasing the IG market shares from 17.2% to 26% at first year, it is possible to achieve savings for almost 10.7 million at third year.

Conclusions

IG, besides being as effective and safe as IL and IA, is less expensive and can reduce the financial burden to the Italian NHS up to €8.8 million at third year.

Zitieren

APA

Lanati, E. P., Malfa, P. L., Iorio, A., Mennini, F. S., Fanelli, F., & Gentile, S. (2018). Analisi di impatto sul budget di differenti analoghi ad azione rapida dell’insulina in Italia. Global & Regional Health Technology Assessment: Italian; Northern Europe and Spanish. https://doi.org/10.1177/2284240318759418

Vancouver

Lanati EP, Malfa PL, Iorio A, Mennini FS, Fanelli F, Gentile S. Analisi di impatto sul budget di differenti analoghi ad azione rapida dell’insulina in Italia. Global & Regional Health Technology Assessment: Italian; Northern Europe and Spanish. 2018. doi:10.1177/2284240318759418

BibTeX
@article{Lanati2018,
  author = {Lanati, Elena P. and Malfa, Paola La and Iorio, Arianna and Mennini, Francesco S. and Fanelli, Francesca and Gentile, Sandro},
  title = {Analisi di impatto sul budget di differenti analoghi ad azione rapida dell’insulina in Italia},
  journal = {Global & Regional Health Technology Assessment: Italian; Northern Europe and Spanish},
  year = {2018},
  doi = {10.1177/2284240318759418}
}
Kostenlos starten →